94 results about "Rat myocardium" patented technology

The invention relates to a method for extracting phenolic glycoside compounds from semen lepidii and application thereof, which can effectively obtain the new function of the semen lepidii. The method adopts the technical scheme that the molecular formula of a semen lepidii new glycoside A is C18H24O12[M+Na]<+>m / z 455.1196; the molecular formula of a semen lepidii new glycoside B is C18H24O12[M+Na]<+>m / z 455.1202. The method has the advantages that two new phenolic glycoside compounds are extracted from a water extract of the semen lepidii, namely the semen lepidii new glycoside A and the semen lepidii new glycoside B; by adopting the two new phenolic glycoside compounds, the cell survival rate of the injured hydrogen peroxide-induced rat myocardial cell H9c2 is obviously improved; the function of protecting the myocardial cell is realized, and a new path is provided for preparation of myocardial protection drugs.

The invention discloses an isolation and culture method for primary mice or rat cardiac muscle cells. The isolation and culture method employs specially-prepared compound enzyme for long-term digestion, so the obtained cells are large in gross quantity and high in both isolation degree and motility rate; due to different acquisition manners, pollution and influence of residual blood in a heart are eradicated and the probability of contamination of the acquired cardiac muscle cells by bacteria, fungi and other cells is low; and the method can realize subculturing, so a good cell culture scheme is provided for related research based on culture of cardiac muscles.

The invention belongs to the traditional Chinese pharmaceutics field, and relates to an application of traditional Chinese medicine radix scrophulariae to the preparation of a drug for preventing and curing cardiac hypertrophy, hypertrophic cardiomyopathy and chronic heart failure. The invention researches the effect of the cardiac hypertrophy and ventricle reconstruction model of a plurality of mice and rats on the traditional Chinese medicine radix scrophulariae. The experimental results show that the radix scrophulariae water or the alcohol abstracts has evident function for preventing the cardiac hypertrophy, the ventricular remodeling and the chronic heart failure caused by various reasons, the mechanism is obviously related with the excessive activation of the neuroendocrine system such as a suppressing renin-angiotensin-aldosterone system and is related with the functions of blood pressure reduction, heart beat slowing and hemodynamics improvement. The figwort can be used for preparing the drug for preventing the diseases of cardiac hypertrophy, hypertrophic cardiomyopathy and chronic heart failure and for reducing the possibility of the incidence rate of arrhythmia and the sudden death of patients with cardiac hypertrophy, hypertrophic cardiomyopathy and chronic heart failure.

The invention relates to the field of medical technology, which discloses a new usage of a petasites tricholobus franch extract and the contained bakkenolide compound in the preparation of drugs for prevention and treatment for cardiovascular and cerebrovascular diseases. The biological activity tests show that, the petasites tricholobus franch extract and the contained bakkenolide compound can significantly reduce the encephalic necrosis percentage of the rats with local cerebral ischemia, improve the behavior score of the ischemic rats and alleviate volume of brain edema and cerebral infarction of the rats with ischemia reperfusion injury, thus prompting that the petasites tricholobus franch extract and the contained bakkenolide compound have significant protective effect on the cerebral ischemia injury. The petasites tricholobus franch extract and the contained bakkenolide compound can further significantly reduce the J-point displacement caused by ISO and the LDH level in plasma, significantly reduce the scope of myocardial ischemic myocardial infarction of the rats caused by coronary artery ligation and lower the LDH level in the plasma of the rats with the myocardial ischemia. As the petasites tricholobus franch extract and the contained bakkenolide compound have good effects on the prevention and the treatment for heart and brain ischemic diseases aspects, the petasitestricholobus franch extract and the contained bakkenolide compound can be used in the preparation of drugs for prevention and treatment for cardiovascular and cerebrovascular diseases, including coronary heart disease, cerebral ischemia, cerebral infarction (stroke), myocardial infarction and so on.

The invention discloses RNA and application of RNA in diseases of a cardiovascular system. According to RNA, the nucleotide sequence of RNA is a sequence 3 in a sequence table. The invention further provides a gene,encoding RNA. The nucleotide sequence of the gene of RNA is a sequence 4 in the sequence table. The experiment of the invention shows that RNA and the application of RNA in the diseases of the cardiovascular system find that by an induction of isoproterenol (ISO), RNAi method Knock down IHP-55 is used in neonatal rat cardiac fibroblasts to obviously promote proliferation of cardiac fibroblasts; ISO induced activation and kinase activity of P38MAPK can be enhanced in the Knock-down HIP-55 cardiac fibroblasts; and HIP-55 is a new protein which has a protective effect on cardiac fibrosis, and provides a new target for clinical diagnosis, treatment and new medicament development.

The medicine for treating cardiac and cerebral vascular diseases is prepared with astragalus root and notoginseng as material, and is Chinese medicine injection, including injection liquid, transfusion liquid and freeze dried powder for injection, prepared through extraction, purification and addition of proper amount of medicinal supplementary material. The medicine has high stability and long effective period, and may be used in intramuscular injection, intravenous injection and intravenous instillation. Pharmacodynamic test shows that the medicine can protect brain against oxygen lack and cardiac muscle damage, raise anaerobic resistance, lower serum LDH and CK activity and reduce myocardial infarction range. The medicine is used in treating cardiac and cerebral vascular diseases and has fast acting, determined curative effect and no toxic side effect.

The invention disclosure an application of sinomenine in the preparation of a medicament for preventing and treating myocardial hypertrophy or a disease based on the myocardial hypertrophy. According to the invention, myocardium of a little mouse is stimulated and induced by means of a beta-receptor stimulant, isoprenaline, and a myocardial hypertrophy model for the little mouse is duplicated; the myocardial hypertrophy of a big rat is induced by means of abdominal aortic coarctation, and a myocardial hypertrophy model for the big rat is duplicated; Chinese herbal medicine monomer, sinomenine, of different doses is applied to the myocardial hypertrophy model for the little mouse and the myocardial hypertrophy model for the big rat respectively. After experimental studies on entire animals in terms of pharmacodynamics, a positive treatment effect is achieved, and a foundation is provided for the screening of new drugs.

The invention relates to a high-purity polyphyllin VI preparation method and an application, and belongs to the field of Chinese herbal medicine extraction and separation. The method includes the specific steps: roughly crushing Chinese paris rhizome or wake robin medicinal materials, performing ethanol extraction; sequentially performing macroporous adsorption resin, silica gel and reverse-phase material column chromatography on extracting solution; taking ethyl acetate, ethanol and water as eluting agents and filtering, washing and drying sedimentation portions after recovering solvents by eluent to obtain high-purity polyphyllin VI. The method has the advantages that the operation steps are easily repeated, conditions are easily controlled and amplified, the solvents are low in toxicity and easy to recover, and the like. The obtained polyphyllin VI is basically free from organic solvent residues, and the purity of the polyphyllin VI reaches 98% or more. After pharmacodynamical research of the influence of mouse normal pressure hypoxia tolerance, mouse brain ischemia caused by common carotid artery ligation, rat myocardium injury caused by ischemia reperfusion, myocardial infarction caused by rat isolated heart myocardial ischemia and the like, the polyphyllin VI serving as a final product is good in effect and can be used for developing products for treating cardiovascular and cerebrovascular diseases.

The invention discloses an application of a morindae officinalis extract and morindae officinalis oligosaccharide pentasaccharide to preparation of a drug for treating myocardial ischemia and / or reperfusion injury and promoting therapeutic angiogenesis. The myocardial ischemia and reperfusion injury belong to secondary injury brought to an organism when the hemoperfusion of myocardium is stopped or poor, i.e., after the myocardium is subjected to ischemia, hypoxia injury, circulation reinstitution and blood supply recovery. The morindae officinalis extract and the morindae officinalis oligosaccharide pentasaccharide both play a role in protecting an in-vivo rat myocardial ischemia reperfusion injury model and an in-vitro purification cultured neonatal rat myocardial cell hypoxia / reoxygenation injury model, and can be used for remarkably reducing the myocardial infarction area and the incidence rate of reperfusion arrhythmias, effectively protecting the form of a myocardial cell and relieving the injury of hypoxia / reoxygenation to the myocardial cell. The therapeutic angiogenesis promotion means that the aims of recovering the blood supply of ischemic myocardium and improving the heart function are achieved through increasing the functional coronary artery branch or side branch under the irritation actions of some methods, including the therapeutic actions of some drugs.

The invention belongs to the technical field of medicines and provides a Chinese medicine composition for treating an ischemic heart disease. The composition comprises an extract from Salvia miltiorrhiza, panax notoginseng saponins, borneol and water-soluble total saponin from Dioscorea nipponica and is obtained by adding the total saponin from the Dioscorea nipponica on the basis of a compound Salvia miltiorrhiza formula. Verified by a rat myocardial ischemia reperfusion injury animal experiment, the effect of the composition for treating the ischemic heart disease is superior to that of the compound Salvia miltiorrhiza tablets; furthermore, the medicine is economic and simple; and experimental basis is provided for secondarily developing the compound Salvia miltiorrhiza tablets and researching the novel Chinese medicine compound with regard to cardiovascular diseases.

The invention discloses new pharmaceutical uses of 7, 4'- di(mono succinate) oxyethoxypropyl daidzein. Pharmacological activity research is carried out to DZ5 by an experimental model for mice under atmospheric hypoxia tolerance, an experimental model for mice acute cerebral ischemia, an experimental model for bilateral common carotid arteries and vagus nerve ligation, an experimental model for mice KCN poisoning, an experimental model for mice NaNO2 poisoning and experimental model for learning and remembering, an action model for rat cortical neuron damage caused by anoxia of DZ5, an effect model for rat myocardial ischemia caused by hypophysin, an experimental model for vitro anti platelet aggregation, an experimental model for vivo anti platelet aggregation, and an effect model for arterial thrombosis in rabbits. Proved by the result, DZ5 has the functions of anti-cerebral ischemia and anoxia, anti-myocardial ischemia and anoxia, antagonistic memory disorders, anti-platelet aggregation and thrombosis, and protection of rat cortical neuron damage caused by anoxia. DZ5 can be mixed with a pharmacologically acceptable carrier or excipient to prepare medicine compositions.

The invention discloses application of lophatherum gracile total flavonoids in preparation of medicine and functional food for preventing and treating myocardial ischemia disease. Shown by the experiment results, the lophatherum gracile total flavonoids are safe without toxic or side effect, and have obvious inhibiting effect on ear swelling model caused by p-dimethylbenzene, can inhibit platelet aggregation and prolong the thrombosis time, and have better protection effect on rat myocardial ischemia and myocardial ischemia reperfusion injury caused by pituitrin. Furthermore, shown by screening results of a great amount of experiments, after being combined with antiplatelet aggregation medication, beta-receptor blocking pharmacon, calcium ion antagonist, statins, RAS system blocking agent, nitrite medication and thrombolysis medication or angiotensin-converting enzyme inhibitor, the the lophatherum gracile total flavonoids show better antiplatelet aggregation, is capable of prolonging the thrombosis time, have better protection effect on rat myocardial ischemia and myocardial ischemia reperfusion injury caused by pituitrin, and play a better synergistic effect.

The invention discloses a medicine compound for treating myocardial ischemia reperfusion of a rat, belonging to the technical field of the medicine compound for preventing and controlling myocardial infarction. The medicine compound for treating myocardial ischemia reperfusion of the rat comprises the following ingredients: 5-15 parts of astragalus extract, 5-10 parts of salvia miltiorrhiza, 2-5 parts of carthamus tinctorius, 1-3 parts of rhodiola rosea, 0.25-0.75 part of procyanidine, 0.25-0.75 part of adiponectin and 1-2 parts of puerarin. According to the medicine compound for treating myocardial ischemia reperfusion of the rat and an application method thereof provided by the invention, the myocardial ischemia reperfusion injury can be obviously relieved; procyanidine which has the effect of relieving inflammation and oxidative stress is added into the medicine compound, so that the oxidation resistance of a body can be promoted; adiponectin has the functions of regulating glucolipid metabolism, resisting inflammation and resisting atherosclerosis; the medicine compound has the function of protecting rat myocardium; the medicine compound can greatly reduce the apoptosis rate of the cells and protect the complete form of the cells.

The invention discloses a screening method of tsRNA related to myocardial ischemia reperfusion. The method is characterized by comprising the following steps of building a rat myocardial ischemia reperfusion model, and screening out differentially expressed tsRNA in a myocardial ischemia reperfusion process by adopting a sequencing method; and building an in-vivo rat myocardial ischemia reperfusion model and an in-vitro myocardial cell hypoxia reoxygenation model, and adopting real-time quantitative PCR for sequencing verification. According to the scheme, the tsRNA participates in the myocardial ischemia reperfusion injury process, and an application of the tsRNA in the aspect of myocardial ischemia reperfusion injury treatment is provided, so that a new idea is provided for people to research a pathophysiology process of myocardial ischemia reperfusion injury, and a new molecular basis or a treatment target is provided for prevention and treatment of myocardial ischemia reperfusion injury.

The invention discloses a preparation method of a rat myocardial ischemia reperfusion model. The preparation method comprises the following steps of: S1, preparing surgical instruments required by anexperiment as follows: 10% water, a 1ml injector, iodophor, a cotton swab, an electric clipper, a surgical plate, four rubber bands, scissors, two large ophthalmic bent forceps, a needle holder, hemostatic forceps, a 6-0 needle suture line, a 3-0 suture line, a suture needle, an electronic scale and a respirator; and S2, selecting a rat which is in a relatively good state, is male and has the weight of 220-250 g, weighing the rat, anesthetizing the rat, lying the rat on the back, fixing the rat on the surgical plate by using the rubber bands, shaving the left side of the sternum, wiping the iodophor on the shaved part for disinfection, longitudinally cutting the skin on the left side of the sternum by 4 cm, bluntly separating subcutaneous muscles, and exposing the pleura between the separated third and fourth ribs. Compared with an existing preparation method of a mouse myocardial ischemia reperfusion model, the preparation method of the rat myocardial ischemia reperfusion model has the advantages that the control is simple, the survival time of the rat is long, and the perfusion effect is good.

The invention discloses a Chinese medicinal composition for treating viral myocarditis, which is prepared from the following Chinese medicinal raw materials in portion by weight: 0 to 10 portions of sun-dried ginseng, 1 to 15 portions of danshen root, 1 to 14 portions of lightyellow sophora root, 1 to 20 portions of radix astragali, and 1 to 18 portions of ophiopogon root. Animal experiments showthat the Chinese medicinal composition for treating the viral myocarditis has protection function on SD rat Coxsackie viral myocarditis and good protection function on the damage to the culturing of myocardial cells of the rat caused by doxorubicin, can be used for treating the viral myocarditis, and has great clinical value.

The invention provides an adult rat cardiac muscle cell separation method which comprises the steps: (a) preheating a perfusion system and fully cleaning a perfusion pipeline; (b) sequentially injecting heparin sodium and pentobarbital sodium into the abdominal cavity of a rat; (c) quickly opening the chest of the rat to expose the heart, taking the lower heart from the aortic root, putting into aperfusion solution, appropriately cleaning surrounding tissues and ligaturing the aorta on a perfusion needle; (d) connecting the intubated heart with the perfusion system and perfusing the heart bya perfusion solution without Ca<2+>; (e) continuously perfusing the heart by a mixed digestive enzyme solution; (f) taking the perfused heart, putting into a transfer solution, removing the atrium andgreat vessels, shearing the ventricle into small pieces, utilizing a suction pipe to blow and beat tissues into monodispersion cells, utilizing a filter screen to filter cell suspension and standing;(g) restoring Ca<2+> in a gradient mode; (h) precipitating cells after resuspending a complete medium to restore Ca<2+> and inoculating into a coated cell culture bottle to be cultured. By means of the adult rat cardiac muscle cell separation method disclosed by the invention, adult rat cardiac muscle cells which have high quality, high yield and long survival time can be obtained.

The invention relates to the field of traditional Chinese medicine, and discloses application of phenethyl alcohol glycoside monomer compounds savatiside E and savatiside A in preparing a medicine for preventing and treating myocardial ischemia and hypoxia. According to the invention, the ability of the savatiside E and savatiside A in clearing oxygen radicals is measured by a DPPH method, and the result indicates that the oxygen radicals can be cleared in a dose-dependent mode. The H2O2 and Na2S2O3-caused myocardial cell damage model is adopted to detect the influence on survival rate of the H2O2 and Na2S2O3-caused rat myocardial cell oxidative damage, and the result indicates that the survival rate of myocardial cells can be improved in a dose-dependent mode to suppress peroxidation damage. Moreover, the in-vivo experiments also indicate that the savatiside E and savatiside A can reduce the area of the coronary artery ligation-caused rat myocardial infarction.

The invention relates to a method used for preparing a compound or a biodrug capable of enhancing CNPase activity and used for treating heart disease. According to the invention, chemical methods involve up-regulating the expression and activity of CNPase by using kaurane compounds; Biological therapeutic agents relate to the preparation of CNPase enzymes expressed by using recombinant adeno-associated viruses and therapies of local intervention; and in a rat myocardial hypertrophy and heart failure model, the method can effectively improve myocardial hypertrophy and myocardial remodeling, inhibit myocardial hypertrophy and fibrosis increase and increase cardiac functions.

A Chinese medicine for treating the acute or chronic myocardial ischemia diseases is prepared from 4 Chinese-medicinal materials: notoginseng, Chuan-xiong rhizome, dalbergia wood and valeriana officinalis. Its advantages are quickly taking its high curative effect (2-3 min), low dosage and no toxic by-effect.

The invention belongs to the technical field of medicine and relates to ziziphora bungeana dripping pills, a production method thereof and an application as a cardiovascular medicament. The ziziphora bungeana dripping pills are characterized by containing aromatic ziziphora bungeana total flavonoids and water-soluble pharmaceutical matrix, and the ratio of the water-soluble pharmaceutical matrix to the aromatic ziziphora bungeana total flavonoids in parts by weight is 1: 1 to 5: 1. The pharmacodynamic test result of the obtained ziziphora bungeana dripping pills shows that the ziziphora bungeana dripping pills have a protecting effect on myocardial ischemic injuries of rats, the anti-myocardial ischemia effect is greatly improved in comparison with the raw pharmaceutical material of the aromatic ziziphora bungeana total flavonoids, and the bioavailability and the clinical efficacy are improved. The obtained ziziphora bungeana dripping pills are convenient to use and good in patient compliance, and the production method is easy for industrialization.

The invention provides a water-soluble tanshinone II A derivative. The water-soluble tanshinone II A derivative is characterized in that the tanshinone II A derivative is a phosphate derivative or phosphamide derivative of compound 1 shown as the formula in the specification, wherein R is hydrogen, alkyl, hydroxy, hydroxymethyl, aldehyde group, carboxyl, alkoxy, aryl, halogenated alkyl, amino or ammonio; R' is phosphoryl shown as formula W in the specification, phosphoryl pharmaceutical salt or phosphamide derivative. Animal experiments of the tanshinone II A derivative show that the derivative has good pharmaceutical effect on rat focal cerebral ischemia-reperfusion injury model and rat myocardial ischemia model, and can be used for preparation of drugs treating cardiovascular and cerebrovascular diseases. The derivative provided by the invention has good water solubility, is suitable for preparation into injection or freeze dried powder dosage forms, and has great clinical application value. The invention also provides a preparation method of the derivative.

The invention belongs to the technical field of biological pharmacy, and discloses a medicine for resisting pressure overload myocardial hypertrophy and ventricular remodeling and application. The application comprises the following steps of: establishing a pressure overload rat myocardial hypertrophy and ventricular remodeling animal model by adopting abdominal aorta constriction; constricting the abdominal aorta for 28d, and sequentially detecting the change of a hemodynamic index and the diameter of a myocardial cell; and transecting the left ventricular myocardial tissue of a rat, observing the form of the myocardial cell under an optical microscope after conventional HE staining, and observing the change effect of leonurine on the pathological form of the left ventricular myocardial tissue of the rat. The invention proves that high and low dosage groups of leonurine have a certain improvement effect on cardiac diastolic and systolic dysfunction of a myocardial hypertrophy rat induced after abdominal aorta constriction; the high and low dosage groups of leonurine can reduce the left ventricular hypertrophy index of the rat after AAC operation; and the high and low dosage groups of leonurine and a positive group can inhibit myocardial cell hypertrophy of the rat after AAC operation and inhibit ventricular remodeling.

The invention discloses application of vinpocetine in preparation of a medicament for preventing and / or treating acute mountain sickness caused by rush entry into plateaus, and further discloses application of vinpocetine in preparation of a medicament for preventing and / or treating myocardial tissue edema and / or brain tissue edema, myocardial tissue inflammatory reaction and / or brain tissue inflammatory reaction caused by low-pressure and low-oxygen environments at the rush entry into plateaus. The invention explores a prevention and treatment effect of vinpocetine on the brain tissue and myocardial tissue edema caused by low pressure and low oxygen at the rush entry into plateaus, and the results show that vinpocetine can down-regulate the expression level of aquaporin genes AQP1 in myocardial tissues and brain tissues under low-pressure and low-oxygen conditions of the plateaus to reduce brain edema and myocardial edema caused by low pressure and low oxygen of the plateaus. The invention simulates the plateau environment at the altitude of 7000m and observes the protective effect of vinpocetine on the myocardial edema and brain edema of rats induced by the low pressure and low oxygen of the plateaus, thereby providing new application and new targets for drug intervention for clinical application of vinpocetine.

The invention relates to the technical field of dracocephalum moldavica extracts and provides a dracocephalum moldavica extract and a preparation method and application thereof. The mass percentage of total flavone in the dracocephalum moldavica extract is 50.3-58.5%. The content of total flavone in the dracocephalum moldavica extract is substantially increased compared with the content of total flavone in an existing dracocephalum moldavica extract. The high dose group and the medium dose group of the dracocephalum moldavica extract have a better curative effect on myocardial ischemia compared with heart-benefiting BaDiRanJiBu subgrains. It is shown that the dracocephalum moldavica extract has a certain protective effect on myocardial ischemia injuries of rats. The dose of the medium dose group of the dracocephalum moldavica extract and the dose of the low dose group of the dracocephalum moldavica extract are 25% and 12.5% of the taking dose of the dracocephalum moldavica extract respectively, and therefore the dose is greatly reduced.

The invention relates to the technical field of natural medicine, and particularly discloses an effective exocarpium part and an application of the effective exocarpium part to preparing of medicine for treating diabetic cardiomyopathy. A preparing method of the effective exocarpium part includes the steps that S1, extraction is carried out through an organic solvent for exocarpium, and organic solvent extract is obtained; S2, the organic solvent extract is fed to a macroreticular resin column, elution is carried out through ethyl alcohol with the volume fraction of 10% to 30% for purification, then elution is carried out through ethyl alcohol with the volume fraction of 50% to 70%, and the ethyl alcohol elution part of 50% to 70% is collected; S3, effective ingredients of the ethyl alcohol elution part of 50% to 70% obtained in the step S2 are gathered in a silica gelcolumn chromatography mode, and the effective exocarpium part is obtained. By means of the effective exocarpium part, the content of rat-myocardium NF-kappaB protein can be remarkably reduced, and the effective exocarpium part can be used for treating diabetic cardiomyopathy.

The invention discloses a construction method of an SD rat myocardial ischemia model, and relates to the technical field of medical tests. The construction method of the SD rat myocardial ischemia model comprises the following steps: anesthetizing a rat; cutting the neck skin of the rat open, separating neck muscles until exposing the trachea, and inserting a trachea cannula needle into the trachea of the rat to be connected with a breathing machine; conducting unhairing and skin preparation on the left chest of the rat, separating shallow chest muscles and deep chest muscles, forming an incision between a third rib and a fourth rib, pre-burying a suture line in the muscles between the third rib and the fourth rib, and ligating the left anterior descending branch of the heart through the suture line; suturing the thoracic cavity of the rat by using the suture line, and exhausting the thoracic cavity of the rat by using an injector connected with a soft silica gel catheter; and pulling out the tracheal intubation needle, and suturing layer by layer. According to the construction method of the SD rat myocardial ischemia model, the success rate of rat myocardial ischemia model construction is increased, the operation difficulty of model construction is reduced, and the operation time of model construction is shortened.

The invention relates to a method for establishing an insulin resistance H9c2 cell model by induction of sodium oleate. The invention can effectively solve the problems that an existing insulin resistance cell model is difficult to establish, the modeling rate is low when high-concentration glucose is adopted to induce insulin resistance, and insulin has great instability and is very difficult tostore as a hormone substance. The technical scheme is as follows: 1) performing cell culture; 2) screening a sodium oleate working concentration by a glucose consumption experiment; and 3) carrying out a process of In-cell Western. According to the invention, sodium oleate is selected to induce rat myocardial cell strains, and the insulin resistance model is successfully established. The fact thatsodium oleate can induce cell insulin resistance is verified for the first time, an induction mechanism of sodium oleate is determined, a new application of sodium oleate is opened up, and the methodis an innovation in inducing establishment of an insulin resistance model by sodium oleate.

The invention belongs to the field of medicament synthesis, and relates to a Danshensu derivative. The Danshensu derivative with a stable structure as above is obtained by combining Danshensu analogue and nitryl. By culturing primary rat cardiocytes, establishing a hypoxia model of cardiocytes and acute and chronic rat models of myocardial infarction, and performing pharmacological tests in vivo and in vitro, results show that the compound has good effect of protecting hypoxic cardiac muscle and certain anti-HIV activity. The compound can be taken as a pilot compound of original innovative medicaments for resisting myocardial ischemia to further prepare medicaments for treating ischemic heart disease and medicaments with anti-HIV activity.